Myasthenia Gravis: Crisis Prevention and Risk Management

Written by Margaret Anne Rockwood | Last updated September 16, 2026
Medically reviewed by Nizar Souayah, MD

Treating myasthenia gravis (MG) requires a nuanced clinical approach that extends beyond the selection of immunosuppressants or the decision to perform a thymectomy. Because MG is marked by fluctuating neuromuscular transmission, there is a need to balance neuromuscular function and compensation.

The additional clinical challenge of anticipating the “myasthenic swing,” that is, the rapid transition from stable weakness to life-threatening respiratory failure, must also be weighed. Finally, long-term multisystemic complications must be managed.

How to Prevent a Myasthenic Crisis

The most crucial safety consideration in MG care is the myasthenic crisis, wherein respiratory failure necessitates mechanical ventilation or non-invasive ventilation (BiPAP) due to bulbar and respiratory muscle weakness.

Approximately 30% to 40% of myasthenic crises are triggered by systemic infections, particularly viral upper respiratory infections or bacterial pneumonia. Other triggers include rapid tapering of corticosteroids, surgical stress, and pregnancy.

Bulbar signs must also be monitored as these are indications of impending crisis. Difficulty clearing secretions, a nasal quality to the voice, or coughing after swallowing liquids are often predictive of respiratory collapse. The Single-Breath Count Test can be a useful bedside surrogate for vital capacity. Finding a count of less than 20 suggests significantly reduced respiratory reserve should be followed by formal pulmonary function tests (FVC and NIF/MIP). If FVC falls below 20 mL/kg or NIF is less than -30 cm H2O, the patient requires elective intubation or ICU admission for BiPAP.

When outpatient management has failed, urgent referral for IVIg or plasma exchange is indicated if:

1. The patient is unable to swallow pills or maintain hydration.
2. There is a noticeable change in speech (dysarthria), progressing through the day.
3. The patient reports orthopnea (shortness of breath when lying flat), indicating diaphragmatic weakness.

Drug Interactions to Be Aware Of

Perhaps the most common safety lapse in MG management is the inadvertent prescription of medications that exacerbate the hallmark neuromuscular blockade.

Antibiotics, and in particular, fluoroquinolones (eg, ciprofloxacin, levofloxacin) carry a Black Box Warning for patients with myasthenia gravis and should be avoided. Aminoglycosides (eg, gentamicin) and macrolides (eg, azithromycin) also carry significant risk. Safer alternatives may include penicillins, cephalosporins, or tetracyclines.

Beta-blockers, including topical ophthalmic drops used for glaucoma, can worsen weakness in MG.

Intravenous magnesium is a potent inhibitor of acetylcholine release and can precipitate an immediate crisis.

In surgical settings, the use of non-depolarizing paralytics (eg, vecuronium) must be handled with extreme caution, as patients with MG are hypersensitive and may experience prolonged, unpredictable paralysis.

Dosing Considerations for Acetylcholinesterase Inhibitors

Acetylcholine (ACh) is the neurotransmitter responsible for signal transmission at the neuromuscular junction. In the synaptic cleft, it binds postsynaptic ACh receptors to initiate muscle contraction. Beyond the neuromuscular junction, ACh also serves as the primary parasympathetic neurotransmitter, mediating “rest and digest” functions including heart rate regulation, glandular secretion, and bronchomotor tone.

Between 75% to 85% of MG cases are AChR-antibody positive, characterized by autoantibodies that block or destroy postsynaptic acetylcholine receptors. For these patients, pyridostigmine, an acetylcholinesterase inhibitor (AChEI), is the first-line symptomatic therapy. It works by inhibiting the enzymatic degradation of ACh in the synaptic cleft, thereby prolonging ACh availability at the remaining functional receptors.

Individuals with MuSK-antibody–mediated MG often respond poorly to AChEIs and may paradoxically worsen; these patients generally require early initiation of immunotherapy, often including plasmapheresis (PLEX).

Below are clinical signs to monitor as well as dosing strategies.

The Cholinergic Peak: Pyridostigmine reaches peak plasma concentration approximately 30–60 minutes after an oral dose. To maximize functional benefit, patients should be advised to time their most physically demanding activities (eg, eating, physical therapy, or other exertion) to coincide with this peak effect window.

Cholinergic vs. Myasthenic Weakness: It is vital to distinguish worsening myasthenic weakness from cholinergic excess. Over-medication with AChEIs can cause muscle fasciculations and paradoxical weakness due to depolarization block at the motor endplate. If a patient presents with increasing weakness accompanied by miosis (pupillary constriction), bradycardia, and SLUDGE phenomenon, the AChEI dose should be reduced, not increased.

The acronym SLUDGE describes the signs of cholinergic excess, indicating the need for AChEI dose reduction or, if severe, emergent intervention. SLUDGE stands for: Salivation, Lacrimation, Urination, Defecation, Gastric upset, and Emesis. Although true cholinergic crisis is less common with modern conservative dosing, it remains a crucial diagnostic consideration, particularly in patients who self-adjust doses, those with renal impairment, or in emergency settings where the clinical picture is ambiguous.

ACh and Heart Rate: Acetylcholine is the primary neurotransmitter of the vagus nerve and normally slows heart rate through parasympathetic activation. Acetylcholinesterase degrades ACh at the sinoatrial node, providing a counterbalance. Excessive AChEI dosing inhibits this degradation, resulting in sustained vagal tone and bradycardia, a constant “slow down” signal to the heart.

ACh and the Lungs: Acetylcholine promotes bronchoconstriction and increases mucus secretion. For patients with asthma or COPD, AChEI therapy requires heightened vigilance. If acetylcholinesterase is excessively inhibited, the airways lose their “off switch,” tightening further and compounding respiratory difficulty during a myasthenic flare.

Corticosteroid Paradox: The Early Exacerbation Risk

While often a necessary course of action, initiating high-dose corticosteroids presents a significant safety hazard. Transient, paradoxical worsening of weakness may occur within the first 7 to 14 days in an estimated 10% of 50% of people with MG, with the risk dependent on the starting dose and the severity of underlying disease.

Clinicians might consider the “Start Low, Go Slow” strategy, starting at 10 to 20 mg and titrating upward helps prevent steroid-induced crisis.

In patients with bulbar symptoms, steroids should only be started after “priming” with intravenous immunoglobin (IVIg) or the more extensive PLEX to provide a safety buffer.  IVIg works by introducing a massive dose of healthy donor antibodies that neutralize and accelerate the clearance of the patient’s harmful ones, while plasmapheresis involves “cleaning the bloodstream of plasms full of pathogenic antibodies and reintroducing their blood cells plus a donor’s albumin.

Long-term Maintenance: Beyond the Neuromuscular Junction

Managing myasthenia gravis in the long term requires multidisciplinary support guided by a neurologist and/or MG specialist. Additional clinicians on the care team should ideally include:

• Endocrinologists: For patients on chronic steroids, endocrinologists can order baseline and annual DXA scans, vitamin D/calcium supplementation, as well as manage blood pressure and glucose.
• Primary Care Physicians: For patients on steroid-sparing immunosuppressants, primary care physicians avoid administering live-attenuated vaccines. Note, however, that the annual influenza vaccine and COVID-19 vaccines (inactivated/mRNA) remain recommended, as the risk of a crisis triggered by the actual infection far outweighs the risk of a vaccine-induced flare.
• Psychologists: As an invisible disorder with fluctuating symptoms, MG can lead to anxiety and depression. Screening for mental health comorbidities is essential for treatment adherence and whole-patient care.
• Gastroenterologists: Practical management of gastrointestinal (GI) side effects (eg, cramping/diarrhea) caused by AChEI overactivation of muscarinic receptors often involves the concurrent use of glycopyrrolate or hyoscyamine.

Sources

• Dishnica N, et al. Single count breath test for the evaluation of respiratory function in myasthenia gravis: A systematic review. J Clin Neurosci. 2023;112:58-63. doi:10.1016/j.jocn.2023.04.011
• Gwathmey KG, et al. Uncontrolled myasthenia gravis can contribute to additional stress burden and adverse mental health experiences (P4-11.019). 2024;102(17 suppl 1):P4-11.019. doi:10.1212/WNL.0000000000205351
• Hehir MK, Silvestri NJ. Generalized myasthenia gravis: Classification, clinical presentation, and diagnosis. Neurol Clin. 2018;36(2):253-260.
• Myasthenia Gravis Foundation of America. Cautionary Drugs List. Published 2023.
• Myasthenia Gravis Foundation of America. Clinical Overview of Myasthenia Gravis.
• Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. 2021;96(3):114-122.
• Sanders DB, et al. International consensus guidance for management of myasthenia gravis. 2016;87(4):419-425.